Patient and Caregiver Perspectives on Patient Burden of Huntington Disease Chorea and the Real‑World Impact of Deutetrabenazine Treatment
Objective: To evaluate self- and caregiver-reported patient burden of Huntington disease (HD) chorea and the impact of deutetrabenazine (DTBZ) treatment on symptom management, quality of…Real-World Effectiveness and Safety of Deutetrabenazine in Chinese Patients With Tardive Dyskinesia
Objective: Assess real-world effectiveness and safety of deutetrabenazine (DTBZ) in Chinese adults with tardive dyskinesia (TD). Background: TD is a movement disorder associated with prolonged…Real-World Evaluation of Deutetrabenazine for Huntington Disease–Associated Chorea in South Korea: Study Design and Baseline Characteristics
Objective: To describe the design and baseline characteristics of a real-world study evaluating the safety and effectiveness of deutetrabenazine (DTBZ) in South Korean patients with…Efficacy of Deutetrabenazine in Patients with Tourette Syndrome: A Meta-Analysis of Randomized Controlled Trials
Objective: To evaluate the efficacy of deutetrabenazine in patients with Tourette syndrome (TS). Background: Deutetrabenazine is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor. While…Effectiveness and Safety of Deutetrabenazine in Chinese Patients with Huntington’s Disease-associated Chorea: A Multicenter Phase 4 Study
Objective: To evaluate the effectiveness and safety of deutetrabenazine (DTBZ) in Chinese patients with Huntington’s Disease (HD)-associated chorea. Background: Chorea is a key symptom of…Efficacy and Adverse Events of Tetrabenazine, Deutetrabenazine, and Valbenazine in Huntington’s Disease
Objective: To compare the efficacy and safety of tetrabenazine, deutetrabenazine, and valbenazine for chorea and neuropsychiatric outcomes in Huntington’s disease (HD). Background: Vesicular monoamine transporter…Baseline assessment of nigrostriatal integrity via VMAT2 PET in participants with Parkinson’s disease from the BIIB122/DNL151 LUMA Phase 2b study
Objective: Evaluate nigrostriatal integrity using vesicular monoamine transporter 2 (VMAT2) PET in participants with early-stage PD enrolled in the LUMA study. Background: LUMA is a…Valbenazine Improves Chorea Across Multiple Body Regions in Adults With Huntington’s Disease
Objective: To evaluate valbenazine’s effects on chorea across body regions in adults with Huntington’s disease (HD) using data from KINECT®-HD (NCT04102579). Background: Once-daily valbenazine is…Decreased Disease Burden in Motor-Related HD-HI Domains Among Adults With Huntington’s Disease Treated With Valbenazine
Objective: To evaluate the effects of valbenazine (VBZ) on mobility, abnormal movements, and hand/arm function as assessed using the Huntington’s Disease Health Index (HD-HI). Background:…Long-Term Safety and Efficacy of Valbenazine for Treating Huntington’s Disease Chorea
Objective: To present safety and efficacy results from a long-term study of once-daily valbenazine for chorea associated with Huntington’s disease (HD). Background: In a 12-week…
- 1
- 2
- 3
- …
- 6
- Next Page »